Two Sigma Securities LLC Buys 1,152 Shares of Medpace Holdings, Inc. $MEDP

Two Sigma Securities LLC raised its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 158.9% during the second quarter, Holdings Channel.com reports. The institutional investor owned 1,877 shares of the company’s stock after purchasing an additional 1,152 shares during the quarter. Two Sigma Securities LLC’s holdings in Medpace were worth $994,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Johnson Financial Group Inc. acquired a new stake in shares of Medpace in the 2nd quarter valued at $27,000. Elyxium Wealth LLC acquired a new stake in shares of Medpace during the fourth quarter worth $30,000. Jones Financial Companies Lllp bought a new stake in Medpace in the second quarter valued at about $30,000. Allied Private Wealth LLC acquired a new position in Medpace in the second quarter valued at about $31,000. Finally, Kilter Group LLC acquired a new position in Medpace in the second quarter valued at about $31,000. Institutional investors own 77.98% of the company’s stock.

Insider Activity

In related news, Director Robert O. Kraft sold 3,858 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $617.81, for a total value of $2,383,510.98. Following the completion of the sale, the director directly owned 955 shares in the company, valued at approximately $590,008.55. This trade represents a 80.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. The trade was a 15.23% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 134,471 shares of company stock valued at $82,151,311. 20.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

MEDP has been the topic of several recent analyst reports. Mizuho lifted their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research note on Friday, July 24th. TD Cowen increased their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their price objective on shares of Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Barclays set a $600.00 price objective on Medpace in a research note on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus price target of $584.18.

Medpace Trading Down 1.1%

Shares of MEDP stock opened at $593.99 on Tuesday. The firm’s fifty day moving average price is $568.10 and its two-hundred day moving average price is $495.34. Medpace Holdings, Inc. has a 1 year low of $373.00 and a 1 year high of $677.90. The firm has a market capitalization of $16.58 billion, a P/E ratio of 34.82, a PEG ratio of 2.68 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the company earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.